HC Wainwright Analysts Increase Earnings Estimates for ATXS

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Analysts at HC Wainwright boosted their FY2024 EPS estimates for Astria Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($1.74) for the year, up from their previous forecast of ($1.82). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.

Other analysts have also recently issued reports about the stock. TD Cowen initiated coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 target price for the company. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Performance

Shares of ATXS opened at $9.75 on Monday. The company has a market capitalization of $550.19 million, a PE ratio of -4.67 and a beta of 0.71. The company’s 50 day moving average price is $11.33 and its 200 day moving average price is $10.62. Astria Therapeutics has a 52 week low of $4.41 and a 52 week high of $16.90.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ATXS. Vanguard Group Inc. lifted its position in shares of Astria Therapeutics by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares during the period. Tidal Investments LLC acquired a new position in Astria Therapeutics in the first quarter valued at about $1,664,000. Sofinnova Investments Inc. acquired a new stake in shares of Astria Therapeutics during the second quarter worth approximately $552,000. ClariVest Asset Management LLC acquired a new stake in shares of Astria Therapeutics during the second quarter worth approximately $731,000. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 2,861 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.